Thrombolytic efficacy of intravenous recombinant tissue plasminogen activator with different doses

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0000933

Enrollment

Registered

2013-11-22

Start date

2013-11-26

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Difference of intravenous ( infusion during 1 hour after bolus) recombinant tissue plasminogen activator doses (0.6 mg/kg and 0.9 mg/kg) in acute middle cerebral infarction patients

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ? Above 20 year old ? Clear onset time, acute middle cerebral artery infarction patients within 3 hours after onset ? Above 4 of National Institute of Health Stroke Scale ? thin-section noncontrast CT before and after intravenous recombinant tissue plasminogen activator ? patients who treated with intravenous recombinant tissue plasminogen activator ? agreement with this study

Exclusion criteria

Exclusion criteria: ? contraindication of intravenous recombinant tissue plasminogen activator I. Comatous mentality II. rapidly improved neurologic deficit or below 4 of National Institute of Health Stroke Scale 4 III. Septic embolism IV. Risk of bleeding: Known AV malformation of aneurysm, within 7 days of non-compressible site arterial puncture, SAH , INR> 1.7, within 48 hours of heparin and aPTT >1.5 times the upper limit of normal V. otherwise relative contraindications ? contraindication of CT ? impossible case of thin section brain CT before and after treatment

Design outcomes

Primary

Measure	Time frame
amount of thrombus and change of Hounsfield Unit	—

Secondary

Measure	Time frame
recanalization	—

Countries

Korea, Republic of

Contacts

Public ContactYoung Dae Kim

Yonsei University Health System, Severance Hospital

Outcome results